Glancy Prongay & Murray LLP Offers Investors Opportunity to Lead Securities Fraud Lawsuit Against Inari Medical, Inc.

Glancy Prongay & Murray LLP (GPM) has recently announced that investors who have suffered substantial losses have the chance to lead the securities fraud class action lawsuit against Inari Medical, Inc. (NASDAQ: NARI). The class period for the lawsuit spans from March 10, 2021, to February 28, 2024, and the lead plaintiff deadline is set for July 12, 2024.

Inari Medical, a leading medical device company, is facing allegations that it repeatedly touted its financial results and product sales success without disclosing that these figures were inflated by bribes and other improper payments to healthcare providers. The complaint filed against the company alleges that these actions rendered the positive statements made by Inari regarding its business, operations, and prospects materially misleading and lacking a reasonable basis throughout the relevant period.

Investors who wish to serve as lead plaintiffs in the Inari lawsuit can submit their contact information at www.glancylaw.com/cases/Inari-Medical-Inc/. Additionally, they can reach out to Charles H. Linehan of GPM at 310-201-9150, toll-free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about their rights.

It is important to note that individuals who wish to be part of the class action need not take any action at this time. They may retain counsel of their choice or choose to remain an absent member of the class action.

For further information about the class action or if you have any questions concerning this announcement or your rights or interests related to the pending lawsuit, please contact Charles Linehan, Esquire, of GPM at 310-201-9150, toll-free at 888-773-9224, by email at shareholders@glancylaw.com, or visit the website at www.glancylaw.com.

Glancy Prongay & Murray LLP is a reputable law firm based in Los Angeles. They are dedicated to representing investors and consumers in various class action lawsuits. The firm’s commitment to seeking justice for its clients has earned them recognition and trust within the legal community.

Please note that this press release may be considered Attorney Advertising in some jurisdictions under applicable law and ethical rules.

Inari Medical, Inc. is a prominent medical device company listed on the NASDAQ stock exchange under the ticker symbol NARI. The company specializes in developing innovative solutions for the treatment of venous diseases. Inari Medical’s dedication to advancing medical technology and improving patient outcomes has positioned them as a key player in the industry.

While this article focuses on the securities fraud lawsuit against Inari Medical, it is important to remember that allegations are not indicative of guilt. The legal process will determine the outcome, and Inari Medical will have the opportunity to present its defense.

More Posts

SWEP, a world-leading supplier of brazed plate heat exchangers (BPHEs), has unveiled its latest innovation …

Village Super Market, Inc. (NASDAQ: VLGEA) is deeply saddened to announce the passing of William …

Vicinity Motor Corp., a leading North American supplier of commercial electric vehicles, has announced the …